Primary Hepatocellular Carcinoma
Conditions
Interventions
Standard treatment group:Targeted-immunotherapy
Add-on treatment group:Traditional Chinese medicine loading combined with standard treatment
Sponsors
Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) HCC confirmed by imaging or pathology;(2)TCM syndrome differentiation meets the diagnostic criteria for Gallbladder Heat and Spleen Cold syndrome;(3) Aged 18–75 years, regardless of gender;(4)Expected survival > 3 months, and Karnofsky Performance Status (KPS) score = 60;(5) Willing to participate in this study, with detailed and complete medical history records.
Exclusion criteria
Exclusion criteria: (1) with other primary malignant tumors; (2) with severe primary diseases of the cardiovascular, pulmonary, renal, or hematopoietic systems; (3) with autoimmune diseases or on long-term immunosuppressive medications that may affect the outcome measures; (4) who are pregnant or breastfeeding; (5) with poor compliance, poor tolerance, allergic diathesis, a history of mental illness, or intellectual disability
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Control Rate;Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| AFP;CEA;DCP;Adverse Event; | — |
Countries
China
Contacts
Public ContactSongtao Li
No. 39, Shi'erqiao Road, Jinniu District, Chengdu, Sichuan Province, China
Outcome results
None listed